ArticlePLOS global public health2026
Bacterial spectrum and proportion of multidrug-resistant bacteria in clinical samples from a regional hospital in Lambaréné, Gabon (2017-2023): Implications for antimicrobial resistance surveillance and public health.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This cross-sectional study investigates the spectrum and proportion of multidrug-resistant (MDR) bacteria isolated from clinical samples processed at the regional microbiology laboratory of Lambaréné, Gabon. Bacteriological results from 2017 to 2023 were retrospectively analysed to assess the rates of non-susceptibility among the most common isolates from urine, blood, stool, and swabs (wound, urethral, ear, and throat). Antimicrobial susceptibility testing and interpretation were performed according to Clinical Laboratory Standards Institute (CLSI) guidelines.A total of 5,401 cultures were reviewed, with 1,050 yielding clinically relevant bacterial isolates. The most frequently identified pathogens were Escherichia coli (273/1050; 26%), Staphylococcus aureus (192/1050; 18%), β-hemolytic Streptococci (160/1050; 15%), and Klebsiella pneumoniae (69/1050; 6.6%). Urine samples predominantly yielded E. coli and K. pneumoniae, while S. aureus was most common in wound and blood cultures. Overall, 23% (242/1050) of isolates were classified as MDR, with E. coli accounting for 40% (96/1050). The proportion of ESBL producers among Enterobacterales was 10% (55/522). Resistance to third-generation cephalosporins was notably high, especially among K. pneumoniae (28/69; 41%) and E. coli (34/273; 13%). Methicillin-resistant S. aureus (MRSA) represented 12% (22/192) of S. aureus isolates; 5.5% (58/1050) of isolates belong to the WHO critical-priority pathogen group.Clinical microbiology data from Lambaréné indicate that urinary infections are mainly associated with E. coli, whereas S. aureus predominates in wound swabs and blood cultures. The detection of WHO critical-priority pathogens in this setting supports the need for sustained microbiological monitoring and locally adapted measures to improve antibiotic use and infection prevention.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.